There’s little clarity from regulators on viable paths forward for new COVID-19 therapeutics, leading to frustration among drug developers who see unfilled medical need as the SARS-CoV-2 pandemic lingers but uncertainty about whether the US Food and Drug Administration will greenlight their pivotal studies.
The current challenges are in part due to the pharmaceutical industry’s COVID-19 successes. The first generation of vaccines and treatments...







